Calsporin® promotes and stabilizes an optimal intestinal microflora by shifting the microbial colonization in favor of mainly Lactobacillus spp., in turn; the proportion of pathogenic bacteria such as Coliforms, Salmonella and Clostridium spp. will be reduced. By doing this, Calsporin® supports the reduction of the ammonia excretion in the faeces.
With a minimum dose of 30 ppm, Calsporin® has demonstrated the ability to improve layer feed conversion rate (up to 2%) and increases egg size consistently over the laying period. In older birds (> 40 weeks), Calsporin® increases laying rate and maintains egg (shell) quality. The proven efficacy of Calsporin® comes with a low input costs and results in economic benefit to the farmer.
In juvenile koi carp, Calsporin® has shown efficacy on growth and feed utilization. These findings are in line with earlier observed results in all of the other major animal species.
Many years of experiences in the Asian and American animal feed industry has led to extended knowledge and possibilities for application for the new authorizations.
CALSPORIN®, manufactured in Japan by Asahi Calpis Wellness Co. Ltd, is being sold and marketed in Europe by Orffa.